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In the EMPA-REG OUTCOME trial (NCT01131676), empagliflozin reduced the primary composite 
outcome of CV mortality (CVM), nonfatal myocardial infarction, or nonfatal stroke, driven by a 
reduction in CVM, as compared to placebo in patients with type 2 diabetes and established CV 
disease. These results led to the first approval of a glucose-lowering drug for CV death prevention in 
the United States. Furthermore, hospitalization for heart failure (HHF) was reduced by 35% (4.1% vs. 
2.7%, HR [95%CI] 0.65 [0.50-0.85]), and the composite of HHF and CVM by 34% (8.5% vs. 5.7%, 
HR[95% CI] 0.66 [0.55-0.79 ]) 1, with similar effect in those with and without HF  at baseline 
(interaction p >0.05) 2. Subsequent analyses of those without established HF at baseline revealed 
consistent effects of empagliflozin on HF outcomes across the spectrum of HF risk 3, suggesting that 
empagliflozin reduced not only HHF but also prevented new-onset HF.  In addition to adjudicated HF 
outcomes (HHF, and HHF or CVM), investigator reported HF and first introduction of loop diuretics 
were reduced by empagliflozin in the overall study population2. However, the study of these 
additional outcomes in patients with and without HF has not yet been explored. The potential interest 
of the study of these subpopulations is to explore whether empagliflozin may be helpful in treating HF 
but also in preventing new-onset HF. 
In the CANVAS Program (Canagliflozin Cardiovascular Assessment Study), canagliflozin, another 
SGLT2 inhibitor, also reduced HHF and HHF or CVM4 but heterogeneity was observed in patients 
with and without HF at baseline for HHF or CVM. Such a heterogeneity was not observed in the 
DECLARE-TIMI 58 trial 5, and a meta-analysis combining the results from these three trials showed 
similar effect on HHF or CVM in those with or without HF6. In this context, we re-evaluated the 
robustness of EMPA-REG findings and further explored the effect of empagliflozin on a broad 
spectrum of endpoints not yet reported for the subgroups of patients with and without HF at baseline. 
The additional HF-related outcomes explored are the first introduction of loop diuretic, the composite 
outcome of first introduction of loop diuretic or first HHF, first mention of edema, and first 
investigator reported HF based on the narrow standardized MedDRA query (SMQ) adverse event 
definition of ‘cardiac failure’. We compare pooled empagliflozin and placebo groups in an intention-
to-treat manner using a Cox proportional hazards model with covariate adjustment for treatment, age, 
sex, geographical region, HbA1c, estimated GFR, and BMI. Patients already using a loop diuretic at 
baseline were not included for the analyses of endpoints including first introduction of loop diuretic. 
However, in order to capture all composite events, patients that experienced an event of HHF were 
included in the analysis of first introduction of the composite of loop diuretic or HHF regardless of 
baseline medication. Subgroup analyses were conducted by HF status at baseline, adding this factor 
and the interaction with treatment to the Cox model. The median follow-up time was 3.1 years.  
At baseline, 80.7% were already using an ACE inhibitor or angiotensin receptor blocker, 64.9% were 
using a beta blocker, and 43.2%  were using a diuretic. During the trial these drugs were newly 
introduced in 27.4%, 19.1% and 21.5% of the study population, respectively. Empagliflozin reduced 
the occurrence of first introduction of loop diuretic: HR (95% CI) 0.62 (0.53-0.73), the composite 
outcome of HHF or first introduction of loop diuretic: HR (95% CI) 0.63 (0.54-0.73), investigator 
reported HF: HR (95% CI) 0.70 (0.56-0.87) or edema onset: HR (95% CI) 0.51 (0.43-0.61), with no 
significant heterogeneity between patients with and without HF at baseline (interaction p >0.05 for all 
the studied outcomes). Figure 1.  
 The biological mechanisms for the reduction in HF events with SGLT2 inhibitors remain 
largely unknown. However, the pronounced effect on “congestion signs”, such as edema and the 
decrease in diuretic need, suggest an important hemodynamic effect. Thus, the reduction in volume 
and sodium load, yielding reduced ventricular filling pressures and cardiac workload, could be an 
important mechanism for both HHF reduction and incident HF prevention. A mediation analysis of 
the EMPA-REG Outcome study associated 50% of the reduction of CVM and HHF with the increase 
in hematocrit, in combination with a plasma volume contraction and reduction of pre-load7. 
Additional suggested mechanisms to explain the benefit of empagliflozin include improved tissue 
oxygenation owing to increased hematocrit, a cardioprotective state related to inhibition of myocardial 
sodium/hydrogen co-transport ion channels, as well as shift in fuel substrate from fatty acids and 
glucose towards the more energy efficient ketones. Ongoing clinical trials in patients with HF (the 
EMPEROR Program [NCT03057951 and NCT03057977] and the EMPERIAL Trials [NCT03448406 
and NCT03448419]), including patients with reduced or preserved ejection fraction, should help 
inform our understanding of the clinical benefits with empagliflozin, and future studies could assess 
the effect of empagliflozin for HF prevention.  
In conclusion, empagliflozin reduces the risk of a broad spectrum of HF outcomes with no 
heterogeneity observed in patients with or without HF at baseline. These results underline the 
robustness of empagliflozin effects on the reduction and prevention of HF events in type 2 diabetes 
patients with established CV disease. 
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Figure 1. Investigator-reported heart failure outcomes in EMPA-REG OUTCOME overall and in 
patients with or without heart failure at baseline 
 
 
Legend: * based on narrow standardised MedRA query (SMQ) ‘cardiac failure’. 
